Consult the medical resource doctors trust

UpToDate is one of the most respected medical information resources in the world, used by over 360,000 doctors and thousands of patients to find answers to medical questions.

  • Content written by a faculty of over 4,000 physicians from leading medical institutions
  • Unbiased: free of advertising or pharmaceutical funding
  • Evidence-based treatment recommendations
  • Continuously updated to incorporate new medical findings

Use of androgens and other performing enhancing drugs by athletes

INTRODUCTION

Some athletes take medications to attempt to improve their performance. They are motivated by a desire to win and the perception that certain medications improve performance. The focus of the general news media is on the athletes who are caught using these medications in popular sporting events, such as the Olympics, baseball, and the Tour de France bicycle race [1]. In comparison, the emphasis of the sports medicine literature is on methods of detection of the newest medications that athletes are using. The focus of this review is on the effects of these compounds that might be encountered by a physician who sees an athlete, competitive or noncompetitive, as a patient. Physicians might also see patients who are taking androgens to improve their appearance [2].

The United States Preventive Services Task Force found insufficient evidence to recommend for or against routine screening for drug abuse in adolescents, including abuse of anabolic steroids [3]. The American Academy of Family Physicians, American Medical Association Guidelines for Adolescent Preventive Services, and the American Academy of Pediatrics all suggest that clinicians discuss the dangers of drug abuse with children and adolescents and include questions about substance abuse as a part of routine adolescent visits. Physicians may also suspect abuse of androgens in adolescents who have problem behavior (eg, fighting, other substance abuse, sexual risk) [4].

HOW THIS AREA OF MEDICINE IS DIFFERENT

This area of medicine differs from most others because athletes who take medications to improve their performance do so surreptitiously. There are several consequences of the clandestine nature of this use:

  • Athletes often obtain the medications from sources other than physicians. These preparations are sometimes meant for veterinary use, sometimes from laboratories that are not regulated by government agencies for manufacturing quality.
  • Athletes obtain their information about the medications from other athletes, trainers, magazines, underground publications, and the Internet.
  • Athletes often take several medications in various patterns, including simultaneously, consecutively ("stacking"), escalating doses ("pyramiding"), intermittently or cyclically in an attempt to increase the overall effect on performance.
  • Athletes may attempt to counter a side effect of one medication with another medication. As examples, an athlete might take human chorionic gonadotropin (hCG) to counteract the decrease in testicular size resulting from high-dose androgen use, an aromatase inhibitor or estrogen receptor antagonist to counteract the gynecomastia from administration of high doses of hCG, and a 5 alpha reductase inhibitor to prevent balding and acne.
  • Athletes discontinue the medications periodically, often to avoid detection when they know they will be tested just before a competition.
  • Physicians who see these athletes are often unaware that they are taking these medications.
  • Physicians' knowledge of the possible effects of these medications is poor because the doses and even the medications used have rarely been studied in a controlled fashion.

EPIDEMIOLOGY

It is difficult to know how commonly athletes take these medications since they are so often taken surreptitiously. In fact, athletes use elaborate schemes to avoid detection.

To continue reading this article you need to subscribe.

Read the rest of this article and others like it

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2009 UpToDate, Inc.
References Top
  1. Catlin, DH, Murray, TH. Performance-enhancing drugs, fair competition, and Olympic sport. JAMA 1996; 276:231.
  2. Parkinson, AB, Evans, NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006; 38:644.
  3. US Preventive Services Task Force. Guide to clinical preventive services, 2nd ed, Williams and Wilkins, Baltimore 1996.
  4. Miller, KE, Hoffman, JH, Barnes, GM, et al. Adolescent anabolic steroid use, gender, physical activity, and other problem behaviors*. Subst Use Misuse 2005; 40:1637.
  5. Curry, LA, Wagman, DF. Qualitative description of the prevalence and use of anabolic androgenic steroids by United States powerlifters. Percept Mot Skills 1999; 88:224.
  6. Korkia, P, Stimson, GV. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. Int J Sports Med 1997; 18:557.
  7. Eaton, DK, Kann, L, Kinchen, S, et al. Youth risk behavior surveillance--United States, 2005. MMWR Surveill Summ 2006; 55:1.
  8. Hershberger, LG, Shipley, EG, Meyer, RK. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 1953; 83:175.
  9. Chang, C, Kokontis, J, Liao, S. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240:324.
  10. Darimont, BD, Wagner, RL, Apriletti, JW, et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 1998; 12:3343.
  11. Leder, BZ, Longcope, C, Catlin, DH, et al. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA 2000; 283:779.
  12. King, DS, Sharp, RL, Vukovich, MD, et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial [see comments]. JAMA 1999; 281:2020.
  13. Brown, GA, Vukovich, MD, Martini, ER, et al. Endocrine responses to chronic androstenedione intake in 30- to 56-year-old men. J Clin Endocrinol Metab 2000; 85:4074.
  14. Acacio, BD, Stanczyk, FZ, Mullin, P, et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men. Fertil Steril 2004; 81:595.
  15. Wallace, MB, Lim, J, Cutler, A, Bucci, L. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc 1999; 31:1788.
  16. Bhasin, S, Storer, TW, Berman, N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men [see comments]. N Engl J Med 1996; 335:1.
  17. Broeder, CE, Quindry, J, Brittingham, K, et al. The andro project: physiological and hormonal influences of androstenedione supplementation in men 35 to 65 years old participating in a high-intensity resistance training program. Arch Intern Med 2000; 160:3093.
  18. Knuth, UA, Maniera, H, Nieschlag, E. Anabolic steroids and semen parameters in bodybuilders. Fertil Steril 1989; 52:1041.
  19. PETERA, V, BOBEK, K, LAHN, V. Serum transaminase (GOT, GPT) and lactic dehydrogenase activity during treatment with methyl testosterone. Clin Chim Acta 1962; 7:604.
  20. Cabasso, A. Peliosis hepatis in a young adult bodybuilder. Med Sci Sports Exerc 1994; 26:2.
  21. Pope, HG Jr, Katz, DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry 1994; 51:375.
  22. O'Connor, DB, Archer, J, Hair, WM, Wu, FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol Behav 2002; 75:557.
  23. Bhasin, S, Woodhouse, L, Casaburi, R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281:E1172.
  24. Hausmann, R, Hammer, S, Betz, P. Performance enhancing drugs (doping agents) and sudden death--a case report and review of the literature. Int J Legal Med 1998; 111:261.
  25. Kennedy, MC, Lawrence, C. Anabolic steroid abuse and cardiac death. Med J Aust 1993; 158:346.
  26. Payne, JR, Kotwinski, PJ, Montgomery, HE. Cardiac effects of anabolic steroids. Heart 2004; 90:473.
  27. Hartgens, F, Cheriex, EC, Kuipers, H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med 2003; 24:344.
  28. Thompson, PD, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261:1165.
  29. Ferenchick, GS, Hirokawa, S, Mammen, EF, Schwartz, KA. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol 1995; 49:282.
  30. Stilger, VG, Yesalis, CE. Anabolic-androgenic steroid use among high school football players. J Community Health 1999; 24:131.
  31. Aitken, C, Delalande, C, Stanton, K. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia. Drug Alcohol Depend 2002; 65:303.
  32. Catlin, DH, Cowan, DA. Detecting testosterone administration [editorial]. Clin Chem 1992; 38:1685.
  33. Sottas, PE, Saudan, C, Schweizer, C, et al. From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Sci Int 2008; 174:166.
  34. Schulze, JJ, Lundmark, J, Garle, M, et al. Doping test results dependent on genotype of UGT2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 2008; 93:2500.
  35. Schulze, JJ, et al, Pharmacogenet Genomics 2008; 18:477.
  36. Perry, PJ, MacIndoe, JH, Yates, WR, et al. Detection of anabolic steroid administration: ratio of urinary testosterone to epitestosterone vs the ratio of urinary testosterone to luteinizing hormone. Clin Chem 1997; 43:731.
  37. Aguilera, R, Chapman, TE, Starcevic, B, et al. Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. Clin Chem 2001; 47:292.
  38. New designer steroid detected in top athletes, News Hour Extra, November 5, 2003.
  39. Richman, J. Four indicted in BALCO case, Oakland Tribune, February 13, 2004.
  40. Handelsman, DJ. Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J Clin Endocrinol Metab 2006; 91:1646.
  41. Liu, H, Bravata, DM, Olkin, I, et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med 2008; 148:747.
  42. Deyssig, R, Frisch, H, Blum, WF. Effect of growth hormone treatment on hormonal parameters, body composition, and strength in athletes. Acta Endocrinol 1993; 338:113.
  43. Yarasheski, KE, Campbell, JA, Smith, K, et al. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol 1992; 262:E261.
  44. Berggren, A, Ehrnborg, C, Rosen, T, et al. Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. J Clin Endocrinol Metab 2005; 90:3268.
  45. Wanjek, B, Rosendahl, J, Strauss, B, Gabriel, HH. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes. Int J Sports Med 2007; 28:346.
  46. Bidlingmaier, M, Strasburger, CJ. Technology insight: detecting growth hormone abuse in athletes. Nat Clin Pract Endocrinol Metab 2007; 3:769.
  47. Powrie, JK, Bassett, EE, Rosen, T, et al. Detection of growth hormone abuse in sport. Growth Horm IGF Res 2007; 17:220.
  48. Nelson, AE, Meinhardt, U, Hansen, JL, et al. Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes. J Clin Endocrinol Metab 2008; 93:2213.
  49. Peddling drugs to the pedal pushers [editorial]. Lancet 1998; 352:415.
  50. Birkeland, KI, Stray-Gundersen, J, Hemmersbach, P, et al. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc 2000; 32:1238.
  51. Berglund, B, Hemmingson, P. Effect of reinfusion of autologous blood on exercise performance in cross-country skiers. Int J Sports Med 1987; 8:231.
  52. Jenkins, P. Doping in sport. Lancet 2002; 360:99.
  53. Vergouwen, PC, Collee, T, Marx, JJ. Haematocrit in elite athletes. Int J Sports Med 1999; 20:538.
  54. Gareau, R, Audran, M, Baynes, RD, et al. Erythropoietin abuse in athletes [letter]. Nature 1996; 380:113.
  55. Skibeli, V, Nissen-Lie, G, Torjesen, P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001; 98:3626.
  56. Beullens, M, Delanghe, JR, Bollen, M. False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood 2006; 107:4711.
  57. Delanghe, JR, Bollen, M, Beullens, M. Testing for recombinant erythropoietin. Am J Hematol 2008; 83:237.
  58. Rich, JD, Dickinson, BP, Merriman, NA, Thule, PM. Insulin use by bodybuilders [letter]. JAMA 1998; 279:1613.
  59. Labotz, M, Smith, BW. Creatine supplement use in an NCAA Division I athletic program. Clin J Sport Med 1999; 9:167.
  60. Smith, J, Dahm, DL. Creatine use among a select population of high school athletes. Mayo Clin Proc 2000; 75:1257.
  61. Graham, AS, Hatton, RC. Creatine: a review of efficacy and safety. J Am Pharm Assoc (Wash) 1999; 39:803.
  62. Dempsey, RL, Mazzone, MF, Meurer, LN. Does oral creatine supplementation improve strength? A meta-analysis. J Fam Pract 2002; 51:945.
  63. Koshy, KM, Griswold, E, Schneeberger, EE. Interstitial nephritis in a patient taking creatine [letter]. N Engl J Med 1999; 340:814.
  64. Edmunds, JW, Jayapalan, S, DiMarco, NM, et al. Creatine supplementation increases renal disease progression in Han:SPRD-cy rats. Am J Kidney Dis 2001; 37:73.
white circle LOG IN
white circle DEMO